Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Diabetes Obesity and...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Diabetes Obesity and Metabolism
Article . 2025 . Peer-reviewed
License: CC BY NC ND
Data sources: Crossref
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Diabetes Obesity and Metabolism
Article . 2025
License: CC BY NC ND
versions View all 4 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study

Authors: Nikki C. C. Werkman; Johannes T. H. Nielen; José Tapia‐Galisteo; Francisco J. Somolinos‐Simón; Maria Elena Hernando; Junfeng Wang; Li Jiu; +8 Authors

Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study

Abstract

AbstractBackgroundDespite the heterogeneity of type 2 diabetes (T2D), all patients are treated according to the same guideline. Some people have more difficulty reaching treatment goals (adequate glycaemic control) and maintaining quality of life (QoL). Therefore, a prediction model identifying who is unlikely to reach these goals within the next year would be useful to allow specific attention to these people.AimTo investigate if machine learning algorithms can predict which individuals are unlikely to reach glycaemic control and likely to deteriorate in QoL in 1 year.MethodsWe used data from The Maastricht Study, including 842 people with T2D and information on HbA1c values, and 964 people with T2D and information on QoL. We evaluated several machine learning algorithms with feature selection methods and hyperparameter tuning in fivefold cross‐validation for the corresponding outcomes.ResultsThe prediction of inadequate glycaemic control showed good performance. The support vector machine classifier performed best in terms of accuracy (0.76 (95% CI 0.71–0.79)), precision (0.79 (95% CI 0.71–0.83)) and area under the receiver operating characteristic curve (AUC‐ROC) (0.85 (95% CI 0.80–0.89)). The multi‐layer perceptron classifier performed best in terms of recall (0.72 (95% CI 0.64–0.79)) and F1‐score (0.73 (95% CI 0.64–0.79)). The prediction of deterioration in QoL showed inadequate performance and did not seem feasible.ConclusionPrediction of glycaemic control after 1 year in T2D is feasible with good model performance. However, the prediction of deterioration in QoL remains a challenge and needs further work.

Keywords

antidiabetic drug, glycaemic control, IDENTIFICATION, SDG 3 - Good Health and Well-being, observational study, type 2 diabetes, DEPRESSION

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
hybrid
Related to Research communities